AU2016318762B2 - A new subpopulation of CD8+CD45RClow Tregs and uses thereof - Google Patents

A new subpopulation of CD8+CD45RClow Tregs and uses thereof Download PDF

Info

Publication number
AU2016318762B2
AU2016318762B2 AU2016318762A AU2016318762A AU2016318762B2 AU 2016318762 B2 AU2016318762 B2 AU 2016318762B2 AU 2016318762 A AU2016318762 A AU 2016318762A AU 2016318762 A AU2016318762 A AU 2016318762A AU 2016318762 B2 AU2016318762 B2 AU 2016318762B2
Authority
AU
Australia
Prior art keywords
human
cells
treg cells
ifny
tregs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016318762A
Other languages
English (en)
Other versions
AU2016318762A1 (en
Inventor
Ignacio ANEGON
Séverine BEZIE
Carole GUILLONNEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Nantes filed Critical Universite de Nantes
Publication of AU2016318762A1 publication Critical patent/AU2016318762A1/en
Application granted granted Critical
Publication of AU2016318762B2 publication Critical patent/AU2016318762B2/en
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, NANTES UNIVERSITÉ reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Amend patent request/document other than specification (104) Assignors: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016318762A 2015-09-07 2016-09-06 A new subpopulation of CD8+CD45RClow Tregs and uses thereof Active AU2016318762B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306366.4 2015-09-07
EP15306366 2015-09-07
PCT/EP2016/070991 WO2017042170A1 (en) 2015-09-07 2016-09-06 A new subpopulation of cd8+cd45rclow tregs and uses thereof

Publications (2)

Publication Number Publication Date
AU2016318762A1 AU2016318762A1 (en) 2018-03-22
AU2016318762B2 true AU2016318762B2 (en) 2022-03-31

Family

ID=54196910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016318762A Active AU2016318762B2 (en) 2015-09-07 2016-09-06 A new subpopulation of CD8+CD45RClow Tregs and uses thereof

Country Status (13)

Country Link
US (1) US20180251731A1 (enExample)
EP (1) EP3347452B1 (enExample)
JP (2) JP2018527932A (enExample)
KR (1) KR102768442B1 (enExample)
CN (1) CN108291203A (enExample)
AU (1) AU2016318762B2 (enExample)
BR (1) BR112018004454A2 (enExample)
CA (1) CA2997646C (enExample)
ES (1) ES2890818T3 (enExample)
IL (1) IL257891B (enExample)
MX (1) MX390494B (enExample)
WO (1) WO2017042170A1 (enExample)
ZA (1) ZA201801265B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
WO2019012024A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
KR102795692B1 (ko) 2018-01-19 2025-04-16 밀테니 비오텍 비.브이. & 씨오. 케이지 키메라 항원 수용체를 발현하는 조절 t 세포
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
EP3765121A4 (en) * 2018-03-14 2021-12-22 Thermogenesis Corp. ACTIVATION / TRANSDUCTION SYSTEMS AND METHODS COMPATIBLE WITH CELL SORTING ACTIVATED BY BUOYANCY
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020120786A1 (en) 2018-12-14 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
BR112021021528A2 (pt) * 2019-04-30 2022-04-19 Univ California Expansão ex vivo livre de contas de células t reguladoras humanas
EP4013780A4 (en) * 2019-08-14 2024-04-10 The Regents Of The University Of California CAR T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES
WO2024028486A1 (en) * 2022-08-04 2024-02-08 Nantes Universite In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460475T1 (de) * 2000-04-11 2010-03-15 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
US20100135974A1 (en) * 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
WO2015150492A2 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
EP3169350B1 (en) * 2014-07-17 2019-01-09 INSERM - Institut National de la Santé et de la Recherche Médicale An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Guillonneau C et al, "CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFN-[gamma], and indoleamine 2,3-dioxygenase", The Journal of Clinical Investigation, 2007, 117(4):1096-1106, doi:10.1172/JCI28801 *
X. L. LI ET AL, "Mechanism and Localization of CD8 Regulatory T Cells in a Heart Transplant Model of Tolerance", THE JOURNAL OF IMMUNOLOGY, US, (2010-07-15), vol. 185, no. 2, doi:10.4049/jimmunol.1000120, ISSN 0022-1767, pages 823 - 833 *

Also Published As

Publication number Publication date
KR102768442B1 (ko) 2025-02-17
JP2018527932A (ja) 2018-09-27
RU2018107363A3 (enExample) 2020-02-27
RU2766691C2 (ru) 2022-03-15
IL257891B (en) 2020-09-30
US20180251731A1 (en) 2018-09-06
IL257891A (en) 2018-05-31
CA2997646C (en) 2024-04-23
JP2021183631A (ja) 2021-12-02
EP3347452A1 (en) 2018-07-18
EP3347452B1 (en) 2021-06-23
KR20180054663A (ko) 2018-05-24
MX390494B (es) 2025-03-20
JP7254128B2 (ja) 2023-04-07
CN108291203A (zh) 2018-07-17
AU2016318762A1 (en) 2018-03-22
ES2890818T3 (es) 2022-01-24
MX2018002849A (es) 2018-09-05
WO2017042170A1 (en) 2017-03-16
NZ740225A (en) 2025-05-30
RU2018107363A (ru) 2019-10-09
BR112018004454A2 (pt) 2018-09-25
ZA201801265B (en) 2022-08-31
CA2997646A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
JP7254128B2 (ja) ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
Lerret et al. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells
US8053235B2 (en) Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use
EP2820125B1 (en) Expansion of alloantigen-reactive regulatory t cells
US20120058096A1 (en) Compositions and methods for generating interleukin-35-induced regulatory t cells
JP2015513403A5 (enExample)
JP2017000149A (ja) 治療における調節性ｔ細胞の使用方法
EP2558857B1 (en) New methods for isolating tr1 cells
US20130101568A1 (en) Il-13 producing tr1-like cells and use thereof
EP3295171A1 (en) Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
RU2766691C9 (ru) НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ
US20180139937A1 (en) Cell culture systems for producing il-33 induced t9 cells and methods of using the cells
Ihantola T-cell dysfunction and autoantigen recognition in type 1 diabetes
Battaglia Induction of tolerance via T regulatory cells. A clinical reality or just a nice experiment in mice?

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Free format text: FORMER NAME(S): UNIVERSITE DE NANTES ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): UNIVERSITE DE NANTES ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Owner name: NANTES UNIVERSITE

Free format text: FORMER NAME(S): UNIVERSITE DE NANTES ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

FGA Letters patent sealed or granted (standard patent)